Review3 Biotech2025
Riding the wave of innovation: nanotechnology in nucleic acid-based cancer therapy.
Review in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acids have lately been explored as one of the significant strategies for cancer treatment. Despite their potential as a promising therapeutic tool in cancer therapy, these often face challenges of rapid degradation, insufficient cellular uptake, and poor targeting abilities. In this regard, nanotechnology has revolutionized nucleic acid-based cancer therapy. The current review explores role of various delivery carriers such as lipidic nanoparticles, polymeric nanoparticles, metallic nanoparticles, and quantum dots in facilitating the transport of nucleic acids, viz., plasmid DNA, siRNA, mRNA, and aptamers. Nanocarriers tend to protect nucleic acids from degradation, improve cellular internalization, and deliver nucleic acids to specific cellular regions, thereby improving their efficacy. In addition, this review provides a comprehensive overview of targeting strategies that address multiple biological barriers of systemic circulation to intracellular trafficking of nucleic acids, as well as advantages, limitations, and applications of each nanoparticles type. By analyzing the current state of scientific research and future advancements in clinical innovation, this review highlights the transformative potential and practical challenges to nanotechnology in nucleic acid-based cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.